Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal ( Focus On AV411's Unique Mechanism of...)

Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal

Focus On AV411's Unique Mechanism of Action and Broad Potential for the Treatment of Neurological Conditions

ALAMEDA, Calif., June 26, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for the treatment of neurological conditions, announced today that Expert Opinion on Investigational Drugs has published an article featuring Avigen's pipeline product, AV411 (ibudilast), a potential first-in-class, non-opioid oral treatment for the management of multiple neurological indications, including neuropathic pain and opioid withdrawal.

"The work on this medication demonstrates the potential of basic neuroscience research, yielding a novel approach to the management of neuropathic pain, enhancement of opiate analgesia, and the management of opiate withdrawal. It's my hope that all these possible avenues will be pursued in addition to further basic research that may uncover other clinical applications of this putative medication," stated Frank Vocci, M.D., Director, Division of Treatment Research and Development, National Institute on Drug Abuse, National Institutes of Health.

According to the National Pain Foundation, neuropathic pain affects up to four million people in the United States. Existing medications, such as opioids, often have modest efficacy in controlling chronic pain because they are targeted specifically to act on neurons. Additionally, opioid use can lead to dependence and withdrawal. Avigen scientists, led by Kirk Johnson, Ph.D., Vice President of Research and Development, in collaboration with researchers at the University of Colorado, Boulder, and the University of Adelaide, Australia, are developing AV411 to address this unmet medical need of controlling chronic pain, while avoiding opioid tolerance and withdrawal.

AV411, in early phase II clinical development in patients with diabetic neuropathic pain, modulat
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
5. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
6. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
7. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
8. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
9. Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research
10. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
11. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development

Post Your Comments:

(Date:11/23/2009)...,, BELLEVUE,Wash.,Nov.23/PRNewswire/--LightS...ofAkbarSeddigh,ChairmanoftheBoard,Elekta,toanewlyc...knownforguidingnumerousmedical-productcompanies,in...tmentofAkbarSeddighbringsadditionalstrengthinbusin...ardJeffHimawan."Mr.Seddighisaworldleaderincancer-t...

(Date:11/23/2009)...,, THEWOODLANDS,Texas,Nov.23/PRNewswire-Firs... ),announcedtodaythattop-linedatafromitsPhase2clin...girritablebowelsyndrome(IBS)willbepresentedatGASTR...wedasignificantimprovementinIBSsymptoms,willbepres...dentofclinicaldevelopment,onNovember25,2009at2:30p...

(Date:11/23/2009)...,, EXTON,Pa.,Nov.23/PRNewswire/--BioTrendsRe...(TM): Feraheme report,thesecondinamulti-phasesyn...G,snewIVironproduct,Feraheme,throughthefirstsixmon...esquantitativeinformationfrom50uniqueNephrologists...sassesstrialanduseofFeraheme,obstaclestouse,reason...

Breaking Medicine Technology:Light Sciences Oncology Elects Akbar Seddigh, Chairman of Elekta AB to Its Board of Directors 2 Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 2 Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 3 Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use 2 Virginia Hospital Center Seeks to Reduce Operating Costs and Improve Supply Chain with Broadlane 49001 1 Virginia Hospital Center Seeks to Reduce Operating Costs and Improve Supply Chain with Broadlane 49001 2 Virginia Hospital Center Seeks to Reduce Operating Costs and Improve Supply Chain with Broadlane 49001 3 Virginia Hospital Center Seeks to Reduce Operating Costs and Improve Supply Chain with Broadlane 49001 4 Virginia Hospital Center Seeks to Reduce Operating Costs and Improve Supply Chain with Broadlane 49001 5 Virginia Hospital Center Seeks to Reduce Operating Costs and Improve Supply Chain with Broadlane 49001 6 A Power Energy Generation Systems Ltd Signs a Biomass Based DG Contract with Sanmenxia New Energy Bio Electricity Co Ltd 12639 1 A Power Energy Generation Systems Ltd Signs a Biomass Based DG Contract with Sanmenxia New Energy Bio Electricity Co Ltd 12639 2 A Power Energy Generation Systems Ltd Signs a Biomass Based DG Contract with Sanmenxia New Energy Bio Electricity Co Ltd 12639 3 The Latin American Digital Radiography Market to Grow Significantly due to the Need to Improve Digital Adoption Observes Frost 26 Sullivan 48998 1 The Latin American Digital Radiography Market to Grow Significantly due to the Need to Improve Digital Adoption Observes Frost 26 Sullivan 48998 2 The Latin American Digital Radiography Market to Grow Significantly due to the Need to Improve Digital Adoption Observes Frost 26 Sullivan 48998 3

[0] Light Sciences Oncology Elects Akbar Seddigh, Chairman of Elekta AB to Its Board of Directors [0] Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 [0] Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use

...vides the foundation for improving understanding o...al development when,retinoblastoma forms, MEMPHIS...tists at St. Jude Children,s Research Hospital hel...f vertebrates, and may translate into,a deeper und...cess of eye,formation and how a rare pediatric eye...

...an. 16 Morria Biopharmaceuticals Plc, a,biopharma...el anti-,inflammatory drugs, today announced the p...and tolerability study of MRX-4 in 16 patients suf...sally administered as a single dose once a week fo... was given without a nasal,allergen challenge (NAC...

Other Medicine Technology:St. Jude Defines Eye Cancer Gene's Role in Retinal Development 2 St. Jude Defines Eye Cancer Gene's Role in Retinal Development 3 Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients 2

St. Jude Defines Eye Cancer Gene's Role in Retinal Development Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients

(Date:11/23/2009)...,Nov.23/PRNewswire-USNewswire/--TheAmericanSociety...publishing,education,andmediacompany,arelaunching"...mdesignedtosparkinterestinthefieldsofscienceandmed...opportunitiesinhematology. ,, "Manyhematologist...theMagnificent,whichmadelearningaboutbloodreallyfu...

(Date:11/23/2009)...f cancer patients and survivors treated with chemo...ten become chronic conditions, hindering patients,... at the University of Rochester Medical Center. ,...ienced sleep troubles at nearly three times the ra... prevalent in younger patients and those with lung...

(Date:11/23/2009)...health care professionals enjoy a pay raise for a ...centives for health care performance may actually ...nt-care performance ratings for 25 medical groups ... the launch of a statewide pay-for-performance pro...octors, productivity. , Reporting in the Dece...

(Date:11/23/2009)...eir odds drop by 63 percent with moderate-to-high ...HealthDay News) -- Moderate-to-high intensity exer...reduce stroke risk in older men but not in women, ... 3,300 men and women, average age 69, in Manhattan...at time, there were 238 strokes among the particip...

(Date:11/23/2009)...ed number of patients who reined in their hyperten...(HealthDay News) -- High blood pressure is better ...-in-hand than by doctors and pharmacists working a...k with pharmacists, medications are intensified, d...y," said Barry L. Carter, a professor in the Unive...

Breaking Medicine News(10 mins):Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 2 Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 3 Health News:Insomnia prevalent among cancer patients who receive chemotherapy 2 Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 2 Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 3 Health News:Vigorous Exercise Cuts Stroke Risk for Men, Not Women 2 Health News:Doctor-Pharmacist Teams Boost Blood Pressure Control 2 Health News:Doctor-Pharmacist Teams Boost Blood Pressure Control 3

[0] New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology [0] Insomnia prevalent among cancer patients who receive chemotherapy [0] Medical 'pay for performance' programs help improve care -- but not always, study finds [1] Vigorous Exercise Cuts Stroke Risk for Men, Not Women [1] Doctor-Pharmacist Teams Boost Blood Pressure Control

...eives Positive Committee Recommendation in Europea...ued positive opinion recommending approval of Qute...heral neuropathic pain in non-diabetic adults eith...ones: , , - European commercial partnership for Q...

...J., March 20 Nuvilex, Inc. (OTC Bulletin Board: N... Board: EFSF), today provided replay information f... at 4:30 p.m. ET. , , The replay will be availab... To listen to the replay, please provide the acco...

...ch will reduce mortality in patients with acute co...ition which includes the ESC Working Group on Acut...cutaneous Cardiovascular Interventions (EAPCI). "S...plasty and stent) in Europe. According to a new re...

... 20 JLL Partners, a leading private equity invest..., Inc., a leading provider of clinical development...nnounced the successful completion of the tender o...shares of common stock of PharmaNet. Parent and P...

...lk to work, maybe you can walk at work instead. , ...3 is National Walk to Work Day. Endorsed by the U...ixth-annual event encourages Americans to turn the...the U.S. Centers for Disease Control and Preventio...

... Linwood Group warns that parents who sav...d be putting their children in danger. , ...-- Commenting on recent research the Linwood Group... car with their children in the back seat after th...

NeurogesX Reports Fourth Quarter and Year-End 2008 Results Nuvilex Provides Conference Call Replay Information 'Stent 4 Life': A campaign is launched to increase the use of primary PCI in acute coronary patients JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period National Walk to Work Day is April 3 Research Shows that Weekend Binge Drinking Can Lead to Parents Drink Driving - Warns the Linwood Group

Arrow QuadPolar EP Catheter

...ABI) is one of the most simple to perform and usef...r disease. With the Portable ABI Kit, you get the ...complete ABI. ...e ankle-arm pressure index (also known as the Ankl...

Speedy-K/Speedy-1 AutoRefractor/Keratometer

Clinitek Atlas Automated Urine Chemistry Analyzer (Carousel)

Medicine Products:

Arrow QuadPolar EP Catheter Portable ABI Kit Speedy-K/Speedy-1 AutoRefractor/Keratometer Clinitek Atlas Automated Urine Chemistry Analyzer (Carousel)

( Focus On AV411's Unique Mechanism of...)Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal,Health